Ellis Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Ellis Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$22K	–	448
2022 Q3	$22K	Hold	500	–	–	0.01%	476
2022 Q2	$18K	Sell	500 -63	-11%	-$2.38K	﹤0.01%	511
2022 Q1	$20K	Hold	563	–	–	﹤0.01%	526
2021 Q4	$17K	Buy	563 +63	+13%	+$1.98K	﹤0.01%	559
2021 Q3	$16K	Hold	500	–	–	﹤0.01%	543
2021 Q2	$19K	Hold	500	–	–	﹤0.01%	518
2021 Q1	$22K	Hold	500	–	–	0.01%	489
2020 Q4	$28K	Hold	500	–	–	0.01%	444
2020 Q3	$23K	Hold	500	–	–	0.01%	456
2020 Q2	$30K	Hold	500	–	–	0.01%	418
2020 Q1	$23K	Hold	500	–	–	0.01%	391
2019 Q4	$30K	Hold	500	–	–	0.01%	405
2019 Q3	$28K	Hold	500	–	–	0.01%	411
2019 Q2	$32K	Buy	+500	New	+$35.3K	0.01%	389

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Ellis Investment Partners's IONS Position: Q4 2022 in Review

Ellis Investment Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 500 shares — an estimated $22K sold.

Ellis Investment Partners first reported a position in IONS in Q2 2019 and held it in 14 quarters. The position peaked at $32K in Q2 2019. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

Ellis Investment Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 500 Ionis Pharmaceuticals shares in Q4 2022, an estimated $22K.
Ellis Investment Partners first reported a position in Ionis Pharmaceuticals in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's Ionis Pharmaceuticals position peaked at $32K in Q2 2019.
338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.